Navigation Links
Making Science Personal: Lilly Oncology to Unveil 76 Studies at,ASCO 2007

37 Thoracic Cancer Studies; 11 Breast Cancer Studies; 9 Targeted Agent Studies

INDIANAPOLIS, May 23, 2007 /PRNewswire-FirstCall/ -- Lilly Oncology will unveil 76 studies at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1-5, 2007. The company will present important data on GEMZAR(R) (gemcitabine HCl for injection), ALIMTA(R) (pemetrexed for injection), and enzastaurin, an investigational, oral, targeted therapy. There will also be numerous studies that continue to use GEMZAR and ALIMTA as chemotherapeutic foundations in innovative combinations with new targeted therapies.

"This is an exciting time in cancer research as we are moving away from 'one-size fits all' treatment," said Richard Gaynor, M.D., Lilly vice president, cancer research and global oncology platform leader. "Lilly's commitment to finding the right drug, at the right dose, for the right patient at the right time will be demonstrated at ASCO this year."

    Key Lilly Abstracts for ASCO 2007:

    -- ALIMTA(R) (pemetrexed for injection)

        -- Phase III Study of ALIMTA in First-line NSCLC

            -- Abstract # 7517: June 2, 2007; 3:00 p.m.

            -- Pemetrexed + carboplatin vs. gemcitabine + carboplatin in the

                treatment of stage IIIB/IV NSCLC


        -- Large Meta-analysis of Diverse Patients with NSCLC

            -- Publication: 2007 ASCO Meeting Program

            -- Effect of race on the safety and efficacy of pemetrexed therapy

               in locally advanced and metastatic non-small cell lung cancer

               (NSCLC)


        -- Phase II Evaluation of ALIMTA Using Accelerated Vitamin

           Supplementation in Small Cell Lung Cancer

            -- Abstract # 7726: June 3, 2007: 8:00 a.m.

            -- The impact of shortened vitamin supplementation lead-in time

               before pemetrexed in patients with relapsed small cell lung

               cancer (SCLC)



        -- Early-phase Trial of ALIMTA +/- Steroids in Head & Neck Cancer

            -- Abstract # 6055: June 4, 2007: 1:00 p.m.

            -- A phase I dose escalation study of pemetrexed in patients with

               advanced head and neck squamous cell cancer


    -- GEMZAR(R) (gemcitabine HCl for injection)

        -- Phase III Study of GEMZAR Combination in Neoadjuvant (Pre-Surgical)

           Breast Cancer

            -- Abstract # 595: June 2, 2007; 2:00 p.m.

            -- Neoadjuvant chemotherapy with a dose-dense sequential

               combination of epirubicin and cyclophosphamide followed by

               paclitaxel and gemcitabine +/- trastuzumab in stage II and III

               breast cancer


    -- Enzastaurin

        -- Phase II Data of Targeted, Oral Agent enzastaurin in Second- &

           Third-line NSCLC

            -- Abstract # 7543: June 2, 2007; 8:00 a.m.

            -- A phase II study of enzastaurin as second- or third-line

               treatment of non-small cell lung cancer (NSCLC)

For more information on Lilly Oncology agents, including full prescribing information, please see the attached fact sheet, or, if you are receiving this electronically, you can view full prescribing information on www.lillyoncology.com.

CONTACT: Gregory L. Clarke, +1-317-276-5222, or Mobile, +1-317-554-7119,or Christine Van Marter, +1-317-651-1473, or Mobile, +1-317-554-7923, bothof Eli Lilly and Company

Ticker Symbol: (:LLY)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
7. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
8. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
9. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... Ky. , Sept. 19, 2017   ZirMed Inc ... predictive analytics, today announced that it has been ranked #1 ... Black Book™ Rankings 2017 User Survey. ZirMed was ... solution for large hospitals and medical centers over 200 beds ... Black Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... MOUNTAIN LAKES, N.J. , Sept. 12, 2017  Consumer reviews ... Embrace Hearing as the number one company for hearing ... Oticon™, ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
Breaking Medicine News(10 mins):